Business
Bionano Genomics Announces Publication of Study in MDS and AML Showing Utility for Refined Diagnostics and Prognostic Stratification
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study evaluating the performance of
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study evaluating the performance of OGM for detection of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) samples. This work is the second independent study, following a recent publication from researchers at MD Anderson Cancer Center, showing that OGM enables better molecular characterization of MDS. This paper extends that research to AML and the findings indicate that OGM may have an even greater impact on the characterization of AML compared to MDS, which led the researchers to recommend integrating OGM into new prognostic scoring methods for both myeloid malignancies. In the study published in Blood Cancer Journal, researchers analyzed samples from 68 adult MDS and AML patients using OGM to evaluate OGM’s performance in the detection of cytogenetic abnormalities that may impact diagnosis and stratification into groups for treatment. In 33% of MDS samples and 54% of AML samples, the study reported more clinically relevant variants were detected using OGM than were found by traditional cytogenetic methods and these variants were reported to be highly relevant to the understanding of pathogenesis of these disorders. Additional findings of the study: The R-IPSS score was changed for 6 cases, which could impact prognosis or assist in patient stratification.In 8 cases, OGM found clinically significant events (mainly complex cytogenetics).OGM also detected balanced structural variants (SVs) identifying partner genes of driver genes not routinely identified by other techniques. “What is gratifying about this study is that it confirms the conclusions that were reported by MD Anderson regarding MDS and it extends that work to include AML. These are areas where innovation can play a big role in improvements in patient management as well as the development of new approaches in disease diagnosis and treatment,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics. The publication can be found here: https://www.nature.com/articles/s41408-022-00718-1 About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. T...